PDM
IDXX icon

Penn Davis McFarland’s Idexx Laboratories IDXX Stock Holding History

Penn Davis McFarland’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-761
Closed -$408K – 78
2025
Q2 		$408K Sell
761
-39
-5% -$18.6K 0.05% 62
2025
Q1 		$336K Hold
800
– – 0.04% 67
2024
Q4 		$331K Hold
800
– – 0.04% 72
2024
Q3 		$404K Buy
+800
New +$389K 0.05% 71

Other funds holding IDXX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Penn Davis McFarland's IDXX Position: Q3 2025 in Review

Penn Davis McFarland sold out of Idexx Laboratories (IDXX) in Q3 2025, closing a stake of 761 shares — an estimated $408K sold.

Penn Davis McFarland first reported a position in IDXX in Q3 2024 and held it in 4 quarters. The position peaked at $408K in Q2 2025. 1,302 funds tracked by Wall St. Rank hold IDXX as of Q3 2025.

  • Penn Davis McFarland reported no remaining Idexx Laboratories position as of Q3 2025 after selling out during the quarter.
  • Penn Davis McFarland sold 761 Idexx Laboratories shares in Q3 2025, an estimated $408K.
  • Penn Davis McFarland first reported a position in Idexx Laboratories in Q3 2024 and held it in 4 quarters.
  • Penn Davis McFarland's Idexx Laboratories position peaked at $408K in Q2 2025.
  • 1,302 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2025.

Based on Penn Davis McFarland's 13F filing for Q3 2025, filed 21 Oct 2025.